Abstract: This disclosure generally relates to therapeutic antibodies for treating Bacillus anthracis (B. anthracis) infection, to specific variants thereof, pharmaceutical composition comprising them and to methods for their use.

Abstract: Provided is a novel lactic acid bacterium strain which is capable of suppressing production of volatile sulfur compounds by oral bacteria, has no cariogenicity and no causative role in infective endocarditis, and is safe in an oral cavity, and provided is an agent for preventing, improving and/or treating oral diseases and discomforts by use of the bacterial strain.

Abstract: Point of care methods to detect the probability or status of tuberculosis infection in individuals by determining presence or absence of one or more peptide of SEQ ID NOS:1-22 in a biological fluid of a subject are described. These methods may be assays based on affinity reagents specifically reactive with these peptides.

Abstract: The invention relates to a method for detecting antibodies against the TpN17 antigen of Treponema pallidum in an isolated sample wherein a peptide sequence of Vibrio cholerae lipoprotein 15 (VcLp15) or a partial sequence thereof is used as a reagent for reduction of interference, i.e. for minimizing false positive results. In addition the invention relates to fusion polypeptides comprising a VcLp15 peptide sequence and a chaperone, to their use as an additive in an immunoassay for said reduction of interferences and for minimizing false positive results and to a reagent kit for detecting antibodies against Treponema pallidum antigens in an isolated sample comprising a TpN17 antigen and said VcLp15-chaperone fusion polypeptide.

Abstract: A purpose is to provide a vaccine which can prevent porcine edema disease in farms where porcine edema disease is anticipated. Meeting this purpose is a vaccine that is a fusion protein in which Stx2eB and a polypeptide having a coiled-coil forming unit are joined or a multimer of the fusion protein, and by immunizing pigs with this vaccine, it is possible to induce potent neutralizing antibodies and to defend against the onset of porcine edema disease.

Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air.

Abstract: The invention generally relates to methods of using compositions that include sets of magnetic particles, members of each set being conjugated to an antibody specific for a pathogen, and magnets to isolate a pathogen from a body fluid sample.

Abstract: The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation.

Abstract: Methods are provided for isolating CD8+ T cells. Furthermore, methods for purifying a subset of IL-13 expressing CD8 T cells are provided, such methods comprising the steps of marking the CD8+ T cells by labeling CD8, or selectively removing non-CD8 cells, and then purifying a subset of IL-13 expressing CD8+ T cells by marking a human biomarker such as C10orf128. Related antibodies and antiserums are also described, such antibodies related to a cell surface domain peptide for biomarker C10orf128, and human homologs of related mouse “activated” CD8IL-13 cell surface biomarkers Tm4sf19 and 1830127L07Rik.

Abstract: An array of micro-chambers (220) with individual ion sensitive field effect transistors (ISFETs) (300) disposed therein for monitoring single cell activity in the microarray to determine the presence or absence of microorganisms in a sample (390). In addition to the presence or absence of a single cell, certain further embodiments contemplate monitoring cell behavior. Cell behavior includes the entire range of cell activity as well as cell response to changes in environmental conditions of changes in response due to the addition of sample constituents.

Abstract: The invention generally relates to conducting an assay on a sample that isolates a pathogen from the sample and allows for analysis of the pathogen with minimal (i.e., at most 24 hrs of culturing) or no culturing of the pathogen. In certain embodiments, the invention provides methods for identifying a pathogen from a sample that involve obtaining a sample including a pathogen, conducting an assay that isolates the pathogen from the sample, culturing the isolated pathogen for at most about 24 hrs, and analyzing the pathogen.

Abstract: Embodiments are directed to compositions and methods for treating parasitic infections. Compounds have been identified from a library of anti-cancer drugs that serve as suitable agents for targeting trypanosomatids.

Abstract: A vaccine for protection against multiple serotypes of Shigella sp., comprising a putative heat shock protein (EL PGI II), and Hypothetical Protein (EL PGIV) is provided.

Abstract: The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy.

Abstract: Ways to increase the effectiveness of probiotics is disclosed. One embodiment relates to a combination of probiotics with secretory IgA and possible uses of this combination. For example, a method of using a composition comprising secretory IgA and at least one probiotic to prepare a product to treat or prevent infection is disclosed.

Abstract: There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments and derivatives of such antibodies, and AIP2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having AIP2 related disorders or conditions. There is also disclosed a method to treat S. aureus infections by administering an anti-AIP2 antibody described herein.

Abstract: The present invention relates to inducing acid resistance in a bacterium and methods of increasing the acid resistance of an acid sensitive bacterium.

Abstract: The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.

Abstract: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and IasI in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become ‘killed but metabolically active’.

Abstract: The present invention relates to a method for diagnosing Q-fever in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of a Coxiella burnetii antigen and (c) determining the expression level of a pro-inflammatory cytokine such as IFN-? in said sample at the end of step (b).